Have a feature idea you'd love to see implemented?
Let us know!
RVMD Revolution Medicines Inc
Price (delayed)
$47.25
Market cap
$7.89B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.71
Enterprise value
$7.7B
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities
Highlights
The company's equity has surged by 74% YoY but it fell by 6% QoQ
RVMD's quick ratio is up by 29% year-on-year but it is down by 17% since the previous quarter
The revenue has dropped by 97% year-on-year and by 84% since the previous quarter
The gross profit has dropped by 97% year-on-year and by 84% since the previous quarter
Key stats
What are the main financial stats of RVMD
Market
Valuations
Earnings
Shares outstanding
167.04M
Market cap
$7.89B
Enterprise value
$7.7B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.82
Price to sales (P/S)
10,516.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10,379.05
Revenue
$742,000
EBIT
-$522.43M
EBITDA
-$511.87M
Free cash flow
-$520.21M
Per share
Balance sheet
Liquidity
EPS
-$3.71
Free cash flow per share
-$3.15
Book value per share
$9.81
Revenue per share
$0
TBVPS
$10.52
Total assets
$1.81B
Total liabilities
$189.59M
Debt
$87.41M
Equity
$1.62B
Working capital
$1.52B
Debt to equity
0.05
Current ratio
15.42
Quick ratio
15.13
Net debt/EBITDA
0.37
Margins
Efficiency
Dividend
EBITDA margin
-68,984.5%
Gross margin
100%
Net margin
-69,974%
Operating margin
-80,961.3%
Return on assets
-30.7%
Return on equity
-34.6%
Return on invested capital
-44.1%
Return on capital employed
-30.7%
Return on sales
-70,408.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RVMD stock price
How has the Revolution Medicines stock price performed over time
Intraday
-2.6%
1 week
-5.5%
1 month
6.42%
1 year
124.79%
YTD
64.75%
QTD
4.19%
Financial performance
How have Revolution Medicines's revenue and profit performed over time
Revenue
$742,000
Gross profit
$742,000
Operating income
-$600.73M
Net income
-$519.21M
Gross margin
100%
Net margin
-69,974%
The revenue has dropped by 97% year-on-year and by 84% since the previous quarter
The gross profit has dropped by 97% year-on-year and by 84% since the previous quarter
RVMD's operating income has dropped by 86% year-on-year and by 9% since the previous quarter
Revolution Medicines's net income has plunged by 75% YoY and by 7% from the previous quarter
Growth
What is Revolution Medicines's growth rate over time
Valuation
What is Revolution Medicines stock price valuation
P/E
N/A
P/B
4.82
P/S
10,516.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10,379.05
The EPS has declined by 19% year-on-year but it has increased by 2.9% since the previous quarter
The company's equity has surged by 74% YoY but it fell by 6% QoQ
The P/B is 55% higher than the last 4 quarters average of 3.1 and 38% higher than the 5-year quarterly average of 3.5
The revenue has dropped by 97% year-on-year and by 84% since the previous quarter
Efficiency
How efficient is Revolution Medicines business performance
RVMD's ROIC is up by 14% year-on-year and by 12% since the previous quarter
Revolution Medicines's return on equity has increased by 5% YoY and by 4.9% QoQ
RVMD's ROA is up by 4.4% QoQ
Dividends
What is RVMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RVMD.
Financial health
How did Revolution Medicines financials performed over time
RVMD's total assets has soared by 68% year-on-year but it is down by 5% since the previous quarter
Revolution Medicines's total liabilities has increased by 33% YoY and by 3.7% from the previous quarter
The debt is 95% less than the equity
The company's equity has surged by 74% YoY but it fell by 6% QoQ
The debt has grown by 38% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.